Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight

The molecular glues market is experiencing significant growth with over 80 active players developing 90+ pipeline candidates. Key companies including Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, and others are advancing promising molecular glue degraders across oncology, immunology, and neurodegenerative diseases. Recent developments include FDA Breakthrough Therapy Designation for Daraxonrasib and multiple clinical trial initiations, positioning molecular glues as a promising therapeutic strategy for previously undruggable proteins.